Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gestational trophoblastic disease

R S Berkowitz1, D P Goldstein

  • 1Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Cancer
|November 15, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease.

Gynecologic oncology·2020
Same author

Important insights for non-molar choriocarcinoma.

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.

Gynecologic oncology·2020
Same author

Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Primary excision margins, sentinel lymph node biopsy, and completion lymph node dissection in cutaneous melanoma: a clinical practice guideline.

Current oncology (Toronto, Ont.)·2019
Same author

HPV Status Improves Classification of Head and Neck Gray Zone Cancers.

Journal of dental research·2019
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
Same journal

Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

Cancer·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
See all related articles

Advances in diagnosing and treating gestational trophoblastic disease (GTD) have improved outcomes. New diagnostic criteria for molar pregnancy and updated chemotherapy regimens offer better remission rates for metastatic GTD.

Area of Science:

  • Gynecology
  • Oncology
  • Reproductive Medicine

Background:

  • Gestational trophoblastic disease (GTD) encompasses molar pregnancy, placental site trophoblastic tumor, and choriocarcinoma.
  • Recent advancements focus on improving diagnostic accuracy and therapeutic efficacy for GTD.

Purpose of the Study:

  • To review recent advances in the diagnosis and management of gestational trophoblastic diseases.
  • To highlight improvements in treatment strategies and patient outcomes.

Main Methods:

  • Review of literature on diagnostic and management strategies for GTD over the past five years.
  • Analysis of updated classification, diagnostic markers, and treatment protocols.

Main Results:

  • Molar pregnancy classification refined based on histopathology and karyotyping.

Related Experiment Videos

  • Early detection of persistent GTD relies on gonadotropin monitoring and clinical suspicion.
  • Improved chemotherapy regimens, including etoposide-based protocols, show higher remission rates (approx. 70%) for high-risk metastatic GTD compared to older triple therapies (approx. 50%).

    • Conclusions:

    • Significant progress in GTD diagnosis and treatment.
    • Patients diagnosed with GTD can expect positive reproductive outcomes with current management.